Risk of selected safety events

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Bleeding ,Arrhythmias, Heart Failure, Acute Renal Failure, Acute Liver Failure, Dyspnoea, Gout

Conditions

Bleeding ,Arrhythmias, Heart Failure, Acute Renal Failure, Acute Liver Failure, Dyspnoea, Gout

Trial Timeline

Jan 1, 2014 → Apr 1, 2015

NCT ID

NCT01276275

About Risk of selected safety events

Risk of selected safety events is a pre-clinical stage product being developed by AstraZeneca for Bleeding ,Arrhythmias, Heart Failure, Acute Renal Failure, Acute Liver Failure, Dyspnoea, Gout. The current trial status is completed. This product is registered under clinical trial identifier NCT01276275. Target conditions include Bleeding ,Arrhythmias, Heart Failure, Acute Renal Failure, Acute Liver Failure, Dyspnoea, Gout.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01276275	Pre-clinical	Completed	Jan 1, 2014	Apr 1, 2015	Bleeding ,Arrhythmias, Heart Failure, Acute Renal Failure, Acute Liver Failure, Dyspnoea, Gout

Competing Products

20 competing products in Bleeding ,Arrhythmias, Heart Failure, Acute Renal Failure, Acute Liver Failure, Dyspnoea, Gout

See all competitors

Product	Company	Stage	Hype Score
60mg edoxaban + 180mg edoxaban + 50 IU/kg Beriplex P/N + 25 IU/kg Beriplex P/N + 10 IU/kg Beriplex P/N	Daiichi Sankyo	Phase 1	33
Elagolix + 0.5 mg estradiol / 0.1 mg norethindrone acetate + 1 mg estradiol / 0.5 mg norethindrone acetate + E2/NETA placebo	AbbVie	Phase 2	52
Elagolix + Placebo + Estradiol/Norethindrone acetate (E2/NETA) + Estradiol + Progesterone	AbbVie	Phase 2	52
Elagolix + Estradiol /norethindrone acetate (E2/NETA)	AbbVie	Phase 3	77
Anticoagulant	AstraZeneca	Pre-clinical	23
Esomeprazole Na + Cimetidine + Esomeprazole Mg	AstraZeneca	Phase 3	77
Tamoxifen + Placebo + Tamoxifen (open label)	Merck	Approved	85
Placebo + Curcumin	Merck	Approved	85
Desogestrel 75 micrograms POP (Cerazette), Etonogestrel 68 mg implant (Nexplanon) + Etonogestrel 68 mg subdermal implant	Merck	Approved	85
Octreotide LAR Depot	Novartis	Phase 1	33
activated recombinant human factor VII	Novo Nordisk	Pre-clinical	22
turoctocog alfa + turoctocog alfa	Novo Nordisk	Phase 3	76
catridecacog + recombinant factor XIII	Novo Nordisk	Phase 1	32
eptacog alfa (activated) + placebo	Novo Nordisk	Phase 3	76
activated recombinant human factor VII + activated recombinant human factor VII	Novo Nordisk	Phase 1	32
activated recombinant human factor VII	Novo Nordisk	Phase 2	51
autologous stored platelets	Novo Nordisk	Phase 2	51
turoctocog alfa pegol	Novo Nordisk	Phase 3	76
recombinant factor XIII	Novo Nordisk	Pre-clinical	22
activated recombinant human factor VII, long acting + activated recombinant human factor VII, long acting	Novo Nordisk	Phase 1	32

Other Products from AstraZeneca

QuetiapineApproved

Dapagliflozin 5 mg + Placebo tabletApproved

QuetiapineApproved

Ticagrelor + ClopidogrelApproved

DurvalumabApproved